Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 459-466

  Pfeiffer, Norbert ^a   Scherzer, Maria Luise ^b   Maier, Hubert ^b   Schoelzel, Sonja ^c   Jasek, Mark C ^d   Stewart, Jeanette A ^e   Stewart, William C ^e  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Department of Surgery ^*

^c UNIVERSITY OF FREIBURG   (Germany)

^d ALCON RESEARCH LTD   (United States)

^e University of South Carolina   (United States)

Author keywords

Efficacy; Intraocular pressure; Ocular hypertension; Primary open angle glaucoma; Safety; Travoprost timolol fixed combination

Indexed keywords

BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRINZOLAMIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

ADJUVANT THERAPY; ADULT; AGED; ARM FRACTURE; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EYE PAIN; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; MALE; MONOTHERAPY; NEPHROLITHIASIS; OBSERVATIONAL STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OPEN STUDY; PROSPECTIVE STUDY; TREATMENT DURATION;

EID: 77953378345     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140(1):1-7.
2. Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114-120.
3. Fletcher AE. Controversy over "contradiction": should randomized trials always trump observational studies? Am J Ophthalmol. 2009;147(3):384-386.
4. Book SA. Essentials of Statistics. New York, NY: McGraw Hill Book Company; 1978:117-122, 205-215.
5. Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressure. Acta Ophthalmologica 1987;65(5):618-621.
6. Miller RG. Beyond ANOVA: Basics of Applied Statistics. New York, NY: Chapman and Hall/CRC; 1998:74-76.
7. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York, NY: McGraw Hill Book Company; 1956:63-67.
8. Zimmerman TJ, Stewart WC; for Latanoprost AXIS Study Group. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19(5):405-415.
9. Hamacher T, Schinzel M, Schölzel-Klatt A, et al. Short-term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/ timolol maleate 0.5% fixed combination from mono- and adjunctive therapies. Br J Ophthalmol. 2004;88(10):1295-1298.
10. Konstas AGP, Bányai L, Blask K-D, et al. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther. 2004;20(5):375-382.
11. Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol. 2004;14(5):407-415.
12. Bayer A, Weiler W, Oeverhaus U, et al. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther. 2004;20(6):470-478.
13. Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007;24(2):376-386.
14. Takahashi I, Tanaka M. Switching to latanoprost monotherapy for 24 weeks in glaucoma patients. Eur J Ophthalmol. 2004;14(5): 401-406.